Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 31 Oct 2019 Planned End Date changed from 1 Jan 2020 to 1 Apr 2021.
- 31 Oct 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Apr 2020.
- 17 Jun 2019 Planned primary completion date changed from 1 May 2019 to 1 Oct 2019.